Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Underweight rating on Bristol-Myers Squibb (NYSE:BMY) but raises the price target from $42 to $43.
October 07, 2024 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Carter Gould maintains an Underweight rating on Bristol-Myers Squibb but raises the price target from $42 to $43, indicating a slight positive adjustment in expectations.
The Underweight rating suggests a cautious outlook, but the slight increase in the price target from $42 to $43 indicates a marginally improved expectation for the stock's performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100